All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
What does the FIGARO trial reveal about predictors of outcome post-transplant?
During the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings), the MDS Hub was pleased to speak with Charles Craddock, Queen Elizabeth...
Post-hoc analysis of combination therapies treosulfan and fludarabine, and busulfan and fludarabine, in patients with MDS
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Matthias Stelljes,...
"The MDS Hub allows you to access the most relevant updates in myelodysplastic syndromes and related disorders. We aim to deliver valuable and up-to-date information and expert opinions to all physicians practicing hemato-oncology."
Are you a healthcare professional? What is your speciality?
Please select or type your speciality
By sharing this information, you can help ensure we continue to develop content that is of most relevance for our audience.
Thank you for submitting.